ClinicalTrials.gg
Status unknownNCT04180150Updated Dec 16, 2019

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

A Phase 2 interventional study of TQ-A3334 and Placebo in Chronic Hepatitis B, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-16.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Planned enrollment
12th of 13
12 · median 116
Started
2019
the only one that year
Phase 2
4 of 13
1 open now
Registered
5th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 12th largest by planned enrollment, is the only one that started in 2019, is one of 4 in phase 2, and was the 5th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. 18 and 65 years old ; 2. positive at least for 6 months ; 3. HBeAg positive chronic hepatitis B, HBV DNA > 10\^5 copies/ml; 4. Fibroscan ≤ 12.4 Kpa,2× ≤ ≤ ULN; 5. New diagnosed chronic hepatitis B subjects;

Exclusion criteria

Exclusion Criteria:

  • 1.Combined with other virus infection ; 2.Has cirrhosis or hepatocellular carcinoma; 3.Has diseases; 4.Has thyroid disease; 5.Has eye diseases; 6.Has abnormalities/diseases ≥ grade 2; 7.Has history of chronic kidney disease, renal insufficiency, renal anemia; 8.Peripheral blood index is low; 9.Has a history of allergy to experimental drugs or their ; 10.Has participated in other clinical trials within 3 months; 11.Breastfeeding or pregnant women.; Men unwilling to use adequate measures during the study; 12.According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.; 13.Has history of drug abuse in the past five years;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    TQ-A3334 combined with entecavir

    Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks

    Drug: TQ-A3334 · Drug: Entecavir Tablet

  • Placebo comparator
    Placebo combined with entecavir

    Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks

    Drug: Placebo · Drug: Entecavir Tablet

Interventions

  • TQ-A3334 is a kind of TLR7 receptor agonist.

  • DrugPlacebo

    Placebo is a treatment which is designed to have no therapeutic value.

  • Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.

06

What researchers measure

Primary outcomes

  1. Cmax

    Cmax is the maximum plasma concentration of TQ-A3334 or metabolite(s).

    Time frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.

  2. Tmax

    To characterize the pharmacokinetics of TQ-A3334 by assessment of time to reach maximum plasma concentration.

    Time frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.

  3. AUC0-t

    To characterize the pharmacokinetics of TQB3804 by assessment of area under the plasma concentration time curve from zero to infinity.

    Time frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.

  4. Cytokine

    Including IFN-α, IFN-γ, TNF-α, IL-6, IL-2, MCP-1 and so on.

    Time frame: Hour 0, 1.5 , 12 , 24 , 72 hours post-dose at week 1 and week 12; Hour 0 at week 7.

Secondary outcomes

  1. HBV biomarker

    Including HBsAg, HBsAb, HBeAb, anti-HBc, HBV-DNA, HBV RNA and HBcrAg.

    Time frame: Day 1 pre-dose, day 84, day 168, day 336 post-dose.

  2. Lymphocyte function

    Analysis of immune cell response to hepatitis B antigen after treatment.

    Time frame: Hour 0 pre-dose, day 56, day 84, day 168 at post-dose.

07

Study locations

1 of 2 sites recruiting
  • The second affiliated hospital of chongqing medical university
    Chongqing, Chongqing, China
    Not yet recruiting
  • The first hospital of Jilin University
    Changchun, Jinlin, China
    Recruiting
    • Junqi Niu, M.D. · Contactjunqiniu@aliyun.com · 0431-88782168
    • Junqi Niu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Sep 2020, 10 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 10 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2019
First posted
Nov 27, 2019
StartActual
Nov 18, 2019
Primary completionEst.
Sep 30, 2020
CompletionEst.
Dec 31, 2021
Last update
Dec 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04180150
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Nov 18, 2019
Primary completion
Sep 30, 2020 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Dec 16, 2019

Study contacts

Junqi Niu, M.D.
Contact
junqiniu@aliyun.com
0431-88782168
Hong Ren, M.D.
Contact
renhong0531@vip.sina.com
023-63693213

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLR7 Agonist JNJ-64794964

Start the discussion